Key clinical point: Overall survival and recurrence were not significantly different for patients with HCC when selection protocols expanded the criteria for tumor size and number and included alpha-fetoprotein levels.
Major finding: The 5-year overall survival in the UCSF and UCSF+ groups was 72% and 69%, respectively, ( P = 0.7); the recurrence risk was 13% and 36%, respectively ( P = 0.1). In addition, the 5-year overall survival rate was 85% among low-risk MVI patients.
Study details: The data come from a retrospective review of 244 adults with preoperative HCC who underwent living donor liver transplantation for HCC, including 159 who met the University of California San Francisco (UCSF) transplant criteria (single tumor ≤ 6.5 cm, up to 3 tumors ≤ 4.5 cm, total tumor diameter ≤ 8 cm), 58 patients whose largest tumor was 10 cm or less (described as UCSF+), and 27 who had macrovascular invasion.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Bhatti ABH et al. J Cancer Res Clin Oncol. 2021 June 12. doi: 10.1007/s00432-021-03665-9.